medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2022, Number 3

<< Back Next >>

Rev Med UAS 2022; 12 (3)

Chronic myeloid leukemia: A science communication paper

Meza-Espinoza JP, González-García JR, Contreras-Gutiérrez JA, Picos-Cárdenas VJ

Language: Spanish
References: 43
Page: 257-271
PDF size: 367.39 Kb.


ABSTRACT

Chronic myeloid leukemia (CML) is a blood disease characterized by leukocytosis and splenomegaly. Its origin has been associated with exposure to ionizing radiation, and more than 90% of patients are carriers of the t(9;22)(q34;q11) translocation, known also as Philadelphia chromosome, which leads to the formation of the BCR/ABL1 hybrid gene, that has the capacity to transform the affected cells and produce leukemia. Treatment is mainly based on specific drugs against BCR/ABL1 protein, with which excellent results are obtained. However, it is common to find patients with relapses, so constant monitoring of the disease by means of cytogenetic and molecular studies is essential.


REFERENCES

  1. Apperley JF. Chronic myeloid leukaemia. The Lancet 2015;385(9976):1447-59.

  2. Liesveld JL, Lichtman MA. Chronic myelo-genous leukemia and related disorders In: Williams hematology. Kaushansky K, Licht-man MA, Prchal JT, Levi MM, Press OW, Burns LJ, Caligiuri MA, (Eds.) McGraw Hill Inc. 9th Ed. New York. 2016: pp 1437-1490.

  3. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, the-rapy and monitoring. Am J Hematol 2020;95(6):691-709.

  4. Cortés J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18(3):671-84.

  5. Johansson B, Fioretos T, Mitelman F. Cyto-genetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002;107(2):76-94.

  6. Hoglund M, Sandin F, Simonsson B. Epide-miology of chronic myeloid leukaemia: an update. Ann Hematol 2015;94(Suppl 2):S241-7.

  7. Huang XL, Cortes J, Kantarjian H. Estima-tions of the increasing prevalence and pla-teau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 2012;118(12):3123-7.

  8. Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Saika K, et al. Decreasing trend in mortality of chronic myelogenous leu-kemia patients after introduction of imatinib in Japan and the U.S. Oncologist 2012;17(12):1547-50.

  9. Santoyo-Sánchez A, Ramos-Peñafiel CO, Saavedra-González A, González-Almanza L, Martínez-Tovar A, Olarte-Carrillo I, et al. Frecuencias de edad y género de pacientescon leucemia observada en dos centros de referencia del Valle de México. Gac Med Mex 2016;152(2):208-12.

  10. Seigel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics 2021. CA Cancer J Clin 2021;71(1):7-33.

  11. Dávila-Rodríguez MI, Cerda-Flores RM, Leal-Garza CH, Arana-Trejo RM, Báez-de la Fuente E, Cortés-Gutiérrez EI. Alteraciones cromosómicas secundarias en pacientes con leucemia mieloide crónica, en un hospi-tal de referencia del noreste de México. Gac Med Mex 2004;140(6):589-92.

  12. Tanaka K, Takechi M, Hong J, Shigeta C, Oguma N, Kamada N, et al. 9;22 transloca-tion and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb survivors. J Radiat Res 1989;30(4):352-8.

  13. Ritch PS, Anderson T, Hanson GA, Pisciotta AV. Chronic granulocytic leukemia following radiation therapy for Hodgkin's disease. Cancer 1982;52(3):462-4.

  14. Iurlo A, Foa P, Maiolo AT, Polli EE. Chronic myelogenous leukemia following radiation therapy for testicular seminoma. Blur 1989;59(6):503-4.

  15. Inskip PD, Monson RR, Wagoner JK, Stovall M, Davis FG, Kleinerman RA, et al. Leu-kemia following radiotherapy for uterine ble-eding. Radiat Res 1990; 122(2):107-19.

  16. Rohrbacher M, Hasford J. Epidemiology and etiology of chronic myeloid leukemia. In: Neoplastic diseases of the blood. Wiernik PH, Dutcher JP, Gertz MA, (Eds.) Springer, 6th Ed. New York, volume 1, 2018: pp 9-17.

  17. Sawyers CL, McLaughlin J, Goga A, Havlik M, Witte O. The nuclear tyrosine kinase c-ABL negatively regulates cell growth. Cell 1994;77(1):121-31.

  18. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic mieloyd leu-kemia. Blood. 2000;96(10):3343-56.

  19. Melo JV. 2 BCR-ABL gene variants. Baillie-res Clin Haematol 1997;10(2):203-22.

  20. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 1986;47(2):277-84.

  21. Ohsaka A, Shiina S, Kobayashi M, Kudo H, Kawaguchi R. Philadelphia chromosome po-sitive chronic myeloid leukemia expressing p190(BCR/ABL). Intern Med 2002;41(12):1183-7.

  22. Pane F, Frigeri F, Sindona M, Luciano L, Fe-rrara F, Cimino R, et al. Neutrophilic chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996;88(7):2410-4.

  23. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341(3):164-72.

  24. Meza Espinoza JP, Gutiérrez Angulo M, Vázquez Cárdenas A, Delgado Lamas JL, Esparza Flores MA, González García JR. Prevalence of the BCR/ABL1 transcripts in Mexican patients with chronic myelogenous leukemia. Rev Invest Clin 2007;59(5):338-41.

  25. Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematolo-gica 2014;99(9):1441-7.

  26. Meza Espinoza JP, Picos Cárdenas VJ, Gu-tiérrez Angulo M, González García JR. Se-condary chromosomal changes in 34 Phila-delphia-chromosome-positive chronic myelocytic leukemia patients from Mexican West. Cancer Genet Cytogenet 2004;148(2):166-9.

  27. Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, DiNardo C, et al. Prognostic significance of additional chromosomal ab-normalities at the time of diagnosis in pa-tients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 2018;93(1):84-90.

  28. Nacheva E, Holloway T, Brown K, Bloxham D, Green AR. Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. British J Haematol 1994;87(2):409-12.

  29. Kantarjian H, Schiffer C, Jones D, Cortés J. Monitoring the response and course of chro-nic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practi-cal advice on the use and interpretation of monitoring methods. Blood 2008;111(4):1774-80.

  30. Mughal TI, Yong A, Szydlo RM, Dazzi F, Ola-varría E, Van Rhee F, et al. Molecular stu-dies in patients with chronic myeloid leu-kaemia in remission 5 years after allogeneicstem cell transplant define the risk of subse-quent relapse. British J Haematol 2001;115(3):569-74.

  31. Hochhaus A, Baccarani M, Silver RT, Schif-fer C, Apperley JF, Cervantes F, et al. Euro-pean LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leu-kemia 2020;34(4):966-84.

  32. Deininger MWN. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program 2008;2008:419-26.

  33. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hemato-poietic cell transplantation. Blood 2012;119(1):296-307.

  34. Vargas-Díez E, García-Díez A, Marín A, Fer-nández-Herrera J. Life-threatening graft-vs-host disease. Clin Dermatol 2005;23(3):285-300.

  35. Doti CA, Bullorsky EO. Hematopoietic stem cell transplantation in the era of tyrosine ki-nase inhibitors. Leuk Lymphoma 2009;50(Suppl. 2):27-31.

  36. Gómez-Almaguer D, Cantú-Rodríguez OG, Gutiérrez Aguirre CH, Ruiz-Argüelles GJ. The treatment of CML at an environment with limited resources. Hematology 2016;21(10):576-82.

  37. Granatowicz A, Piatek CI, Moschiano E, El-Hemaidi I, Armitage JD, Akhtari M. An over-view and update of chronic myeloid leukemia for primary care physicians. Korean J Fam Med 2015;36(5):197-202.

  38. Steegmann JL, Baccarani M, Breccia M, Ca-sado LF, García Gutiérrez V, Hochhaus A, et al. European LeukemiaNet recommenda-tions for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016;30(8):1648-71.

  39. Thompson PA, Kantarjian H, Cortes JE. Diagnosis and treatment of chronic myeloid leukemia (CML) in 2015. Mayo Clin Proc 2015;90(10):1440-54.

  40. Cortés JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromo-some-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018;132(4):393-404.

  41. Quintas-Cardama A, Cortés JE, Kantarjian HM. Early cytogenetic and molecular res-ponse during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications. Cancer 2011;117(23):5261-70.

  42. Ayala M. Estado actual del tratamiento de la leucemia mieloide crónica en México Rev Hematol Mex 2013;14(Supl. 1):S5-S7.

  43. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376(10):917-27.




2020     |     www.medigraphic.com